Clinical implications of hedgehog signaling pathway inhibitors

Hailan Liu, Dongsheng Gu, Jingwu Xie

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Hedgehog was first described in Drosophila melanogaster by the Nobel laureates Eric Wieschaus and Christiane Nüsslein-Volhard. The hedgehog (Hh) pathway is a major regulator of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and carcinogenesis. The first link of Hh signaling to cancer was established through studies of a rare familial disease, Gorlin syndrome, in 1996. Follow-up studies revealed activation of this pathway in basal cell carcinoma, medulloblastoma and, leukemia as well as in gastrointestinal, lung, ovarian, breast, and prostate cancer. Targeted inhibition of Hh signaling is now believed to be effective in the treatment and prevention of human cancer. The discovery and synthesis of specific inhibitors for this pathway are even more exciting. In this review, we summarize major advances in the understanding of Hh signaling pathway activation in human cancer, mouse models for studying Hh-mediated carcinogenesis, the roles of Hh signaling in tumor development and metastasis, antagonists for Hh signaling and their clinical implications.

Original languageEnglish
Pages (from-to)13-26
Number of pages14
JournalChinese Journal of Cancer
Volume30
Issue number1
StatePublished - 2011

Fingerprint

Hedgehogs
Neoplasms
Carcinogenesis
Basal Cell Nevus Syndrome
Medulloblastoma
Gastrointestinal Neoplasms
Basal Cell Carcinoma
Rare Diseases
Drosophila melanogaster
Ovarian Neoplasms
Cell Differentiation
Lung Neoplasms
Prostatic Neoplasms
Leukemia
Stem Cells
Maintenance
Cell Proliferation
Breast Neoplasms
Neoplasm Metastasis

Keywords

  • Animal model
  • Cancer
  • Clinical trials
  • Hedgehog
  • PTCH1
  • Signal transduction
  • Smoothened

ASJC Scopus subject areas

  • Oncology

Cite this

Clinical implications of hedgehog signaling pathway inhibitors. / Liu, Hailan; Gu, Dongsheng; Xie, Jingwu.

In: Chinese Journal of Cancer, Vol. 30, No. 1, 2011, p. 13-26.

Research output: Contribution to journalArticle

Liu, Hailan ; Gu, Dongsheng ; Xie, Jingwu. / Clinical implications of hedgehog signaling pathway inhibitors. In: Chinese Journal of Cancer. 2011 ; Vol. 30, No. 1. pp. 13-26.
@article{aab641df7cb5463d8b5ec0fc50c9e09e,
title = "Clinical implications of hedgehog signaling pathway inhibitors",
abstract = "Hedgehog was first described in Drosophila melanogaster by the Nobel laureates Eric Wieschaus and Christiane N{\"u}sslein-Volhard. The hedgehog (Hh) pathway is a major regulator of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and carcinogenesis. The first link of Hh signaling to cancer was established through studies of a rare familial disease, Gorlin syndrome, in 1996. Follow-up studies revealed activation of this pathway in basal cell carcinoma, medulloblastoma and, leukemia as well as in gastrointestinal, lung, ovarian, breast, and prostate cancer. Targeted inhibition of Hh signaling is now believed to be effective in the treatment and prevention of human cancer. The discovery and synthesis of specific inhibitors for this pathway are even more exciting. In this review, we summarize major advances in the understanding of Hh signaling pathway activation in human cancer, mouse models for studying Hh-mediated carcinogenesis, the roles of Hh signaling in tumor development and metastasis, antagonists for Hh signaling and their clinical implications.",
keywords = "Animal model, Cancer, Clinical trials, Hedgehog, PTCH1, Signal transduction, Smoothened",
author = "Hailan Liu and Dongsheng Gu and Jingwu Xie",
year = "2011",
language = "English",
volume = "30",
pages = "13--26",
journal = "Cancer Communications",
issn = "1000-467X",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Clinical implications of hedgehog signaling pathway inhibitors

AU - Liu, Hailan

AU - Gu, Dongsheng

AU - Xie, Jingwu

PY - 2011

Y1 - 2011

N2 - Hedgehog was first described in Drosophila melanogaster by the Nobel laureates Eric Wieschaus and Christiane Nüsslein-Volhard. The hedgehog (Hh) pathway is a major regulator of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and carcinogenesis. The first link of Hh signaling to cancer was established through studies of a rare familial disease, Gorlin syndrome, in 1996. Follow-up studies revealed activation of this pathway in basal cell carcinoma, medulloblastoma and, leukemia as well as in gastrointestinal, lung, ovarian, breast, and prostate cancer. Targeted inhibition of Hh signaling is now believed to be effective in the treatment and prevention of human cancer. The discovery and synthesis of specific inhibitors for this pathway are even more exciting. In this review, we summarize major advances in the understanding of Hh signaling pathway activation in human cancer, mouse models for studying Hh-mediated carcinogenesis, the roles of Hh signaling in tumor development and metastasis, antagonists for Hh signaling and their clinical implications.

AB - Hedgehog was first described in Drosophila melanogaster by the Nobel laureates Eric Wieschaus and Christiane Nüsslein-Volhard. The hedgehog (Hh) pathway is a major regulator of cell differentiation, proliferation, tissue polarity, stem cell maintenance, and carcinogenesis. The first link of Hh signaling to cancer was established through studies of a rare familial disease, Gorlin syndrome, in 1996. Follow-up studies revealed activation of this pathway in basal cell carcinoma, medulloblastoma and, leukemia as well as in gastrointestinal, lung, ovarian, breast, and prostate cancer. Targeted inhibition of Hh signaling is now believed to be effective in the treatment and prevention of human cancer. The discovery and synthesis of specific inhibitors for this pathway are even more exciting. In this review, we summarize major advances in the understanding of Hh signaling pathway activation in human cancer, mouse models for studying Hh-mediated carcinogenesis, the roles of Hh signaling in tumor development and metastasis, antagonists for Hh signaling and their clinical implications.

KW - Animal model

KW - Cancer

KW - Clinical trials

KW - Hedgehog

KW - PTCH1

KW - Signal transduction

KW - Smoothened

UR - http://www.scopus.com/inward/record.url?scp=79954486712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954486712&partnerID=8YFLogxK

M3 - Article

C2 - 21192841

AN - SCOPUS:79954486712

VL - 30

SP - 13

EP - 26

JO - Cancer Communications

JF - Cancer Communications

SN - 1000-467X

IS - 1

ER -